Education
About Us
Working with TipRanks
Follow Us
Biogen (BIIB)
NASDAQ:BIIB
BIIB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$110.04 - $207.59
Previous CloseN/A
Volume268.56K
Average Volume (3M)1.37M
Market Cap
$18.77B
Enterprise Value$22.26B
Total Cash (Recent Filing)$2.76B
Total Debt (Recent Filing)$6.59B
Price to Earnings (P/E)12.2
Beta0.63
Next Earnings
Oct 22, 2025EPS Estimate
3.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.47
Shares Outstanding146,614,600
10 Day Avg. Volume1,798,787
30 Day Avg. Volume1,372,906
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)1.33
Price to Sales (P/S)2.30
P/FCF Ratio8.86
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue2.23
Enterprise Value/Gross Profit2.95
Enterprise Value/Ebitda7.97
Forecast
1Y Price Target
$168.50Price Target Upside30.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering26
Bulls Say, Bears Say
Bulls Say
Leqembi Sales PerformanceLeqembi sales exceeded expectations with impressive performance across various regions, highlighting strong market demand.
Pipeline DevelopmentBIIB's evolving pipeline shows a promising mix of high-risk, high-reward neuro investments alongside solid immunology and rare disease developments.
Bears Say
Revenue DiversificationWith approximately 90% of Biogen's revenue still dependent on legacy products, there is a pressing need for revenue diversification.
Technological AdvancementsBIIB appears to be lagging in adopting new technologies and lacks a significant presence in the BBB-shuttle advancements.
Biogen News
BIIB FAQ
What was Biogen’s price range in the past 12 months?
Biogen lowest stock price was $110.03 and its highest was $207.59 in the past 12 months.
What is Biogen’s market cap?
Biogen’s market cap is $18.77B.
When is Biogen’s upcoming earnings report date?
Biogen’s upcoming earnings report date is Oct 22, 2025 which is in 69 days.
How were Biogen’s earnings last quarter?
Biogen released its earnings results on Jul 31, 2025. The company reported $5.47 earnings per share for the quarter, beating the consensus estimate of $3.899 by $1.571.
Is Biogen overvalued?
According to Wall Street analysts Biogen’s price is currently Undervalued.
Does Biogen pay dividends?
Biogen does not currently pay dividends.
What is Biogen’s EPS estimate?
Biogen’s EPS estimate is 3.84.
How many shares outstanding does Biogen have?
Biogen has 146,614,600 shares outstanding.
What happened to Biogen’s price movement after its last earnings report?
Biogen reported an EPS of $5.47 in its last earnings report, beating expectations of $3.899. Following the earnings report the stock price went up 1.074%.
Which hedge fund is a major shareholder of Biogen?
Currently, no hedge funds are holding shares in BIIB
Biogen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$168.50 (30.69% Upside)
$168.50 (30.69% Upside)
Blogger Sentiment
Neutral
BIIB Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 137.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $300.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.86%
12-Months-Change
Fundamentals
Return on Equity
9.13%
Trailing 12-Months
Asset Growth
5.69%
Trailing 12-Months
Company Description
Biogen
Biogen Inc. is a global biotechnology company dedicated to discovering, developing, and delivering innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen focuses on areas such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease, offering a range of products including well-known medications like Tecfidera, Avonex, and Spinraza. The company's commitment to research and development drives its pipeline of potential treatments, positioning it as a leader in the biotechnology sector.
BIIB Company Deck
BIIB Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong quarter with significant growth from new product launches and positive developments in the pipeline, offset by challenges in international markets and partnership disagreements. The company's financial outlook has improved, leading to raised guidance. Overall, the highlights outweigh the lowlights, indicating a positive sentiment.View all BIIB earnings summariesBIIB Revenue Breakdown
74.55% Product revenue
18.09% Revenue from anti-CD20 therapeutic programs
6.74% Contract manufacturing, royalty and other revenue
0.62% Alzheimer's collaboration revenue
BIIB Stock 12 Month Forecast
Average Price Target
$168.50
▲(30.69% Upside)
Technical Analysis
Ownership Overview
0.18% Insiders
32.50% Mutual Funds
0.39% Other Institutional Investors
35.05% Public Companies and Individual Investors